Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-10-26
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-10 (study day 77.0); relationship: PROBABLE
Data queries
No data queries.